Sumitomo Pharma Oncology, Inc.

Sumitomo Dainippon Pharma Oncology, Inc.

Sumitomo Pharma America, Inc.

Yuka Arikawa

Adam Siddiqui-Jain

Paul Flynn

Hiroaki Tanaka

Shuji Masumoto

Hirotaka Kurebayashi

Takahiko Hashizuka

Yuji Fujiwara

David J Bearss

Steven L Warner

Clifford J Whatcott

Jason Marc Foulks

Stephen Patrick Anthony

A crystalline form and/or polymorph of a compound having the following structure (I), including tautomeric and zwitterionic forms thereof, are provided: Methods associated with preparation and use of the polymorphs, and pharmaceutical compositions comprising the same are also provided. Also provided are methods for preparing a compound having formula (I), or a salt, tautomer or zwitterionic form thereof.

CDK9 inhibitors and polymorphs thereof for use as agents for treatment of cancer

Methods for treating a disease in a subject in need thereof by administering an ACVR1 inhibitor having the following formula (I) are disclosed: including stereoisomers, tautomers, pharmaceutically acceptable salts and prodrugs thereof, wherein R, R, R, and Rare as defined herein. Subjects that may benefit from treatment may have mutations in their ACVR1 gene. Various diseases may be treated using the described methods, including cancers (e.g., diffuse intrinsic pontine glioma (DIPG)) and genetic disorders (e.g., fibrodysplasia ossificans progressiva (FOP)).

Methods for treating diseases associated with abnormal ACVR1 expression and ACVR1 inhibitors for use in the same

Growing community of inventors

Minoh, Japan

Yuka Arikawa